Literature DB >> 22840424

Vertical transmission of Babesia microti, United States.

Julie T Joseph1, Kerry Purtill, Susan J Wong, Jose Munoz, Allen Teal, Susan Madison-Antenucci, Harold W Horowitz, Maria E Aguero-Rosenfeld, Julie M Moore, Carlos Abramowsky, Gary P Wormser.   

Abstract

Babesiosis is usually acquired from a tick bite or through a blood transfusion. We report a case of babesiosis in an infant for whom vertical transmission was suggested by evidence of Babesia spp. antibodies in the heel-stick blood sample and confirmed by detection of Babesia spp. DNA in placenta tissue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22840424      PMCID: PMC3414010          DOI: 10.3201/eid1808.110988

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Babesiosis is an emerging infection in the United States, principally caused by Babesia microti (). The most common route of infection is the bite of an Ixodes scapularis tick; transmission can also occur by transfusion of infected blood products, and vertical transmission in animals has been documented (,) and is a potential route of transmission for humans. We report a case of babesiosis in an infant for whom vertical transmission was suggested by Babesia spp. antibodies in a heel spot blood sample and confirmed by detection of Babesia DNA in placenta tissue.

The Case-Patient

A 6-week-old girl from Yorktown Heights, New York, was admitted to the hospital on September 16, 2002, with a 2-day history of fever, irritability, and decreased oral intake. The mother was asymptomatic during and after her pregnancy. The infant was delivered vaginally and full term at 3,430 g without complications. The infant’s mother had visited parks in Westchester and Dutchess Counties in New York during the pregnancy but was unaware of any tick bites. The infant had no known tick exposure, and neither mother nor infant had a history of blood transfusion. During examination, the infant was alert but irritable and pale. Axillary temperature was initially 36.8°C but increased to 38.1°C on the same day. Her conjunctivae were icteric, she had a palpable spleen tip, and her liver was palpable 3 cm below the costal margin. Initial laboratory findings included hemoglobin 7.1 g/dL, platelet count 100 × 103/μL, and leukocyte count 19.7 × 103 cells/μL with a differential of 4% segmented neutrophils, 80% lymphocytes, and 16% monocytes. Reticulocyte count was 5.5%. Total bilirubin concentration was 2 mg/dL with a direct fraction of 0.4 mg/dL; aspartate aminotransferase level was 66 U/L, alanine aminotransferase level was 50 U/L, and alkaline phosphatase level was 339 U/L. Cultures of blood, urine, and cerebrospinal fluid samples yielded negative results. Lyme disease serologic test result was negative. Routine examination of a peripheral blood smear showed B. microti in 4% of erythrocytes (Figure); a blood sample from the infant was positive by PCR for B. microti DNA. Total B. microti antibody titer was >256 by indirect immunofluorescence assay, with a polyvalent secondary antibody (anti-IgG+IgA+IgM) () that was presumed to be principally IgG because test results for IgM were negative (Technical Appendix). The heel-stick blood sample obtained on the infant’s third day of life as part of newborn screening was tested and found to be negative for B. microti by PCR () and for IgM but total antibody positive (>128) (Technical Appendix).
Figure

Peripheral blood smear of 6-week-old infant with suspected congenital babesiosis. Thin arrows indicate Babesia spp. parasites; thick arrow shows the classic tetrad formation or Maltese cross.

Peripheral blood smear of 6-week-old infant with suspected congenital babesiosis. Thin arrows indicate Babesia spp. parasites; thick arrow shows the classic tetrad formation or Maltese cross. Examination of the placenta showed focal basal decidual inflammation, mild chorangiosis, and villus dysmaturity. Babesia spp. piroplasms were not detected in maternal or fetal blood by histologic examination of hematoxylin and eosin–stained sections of formalin-fixed, paraffin-embedded tissue of the placenta disk, amnion/chorion, and umbilical cord. Babesia DNA was detected by real-time PCR testing of paraffin-embedded placenta tissue (Technical Appendix) (). Cycle threshold values were relatively high (37.1–38.2), indicating that the amount of parasite DNA in the sample was close to the limit of detection; results were reproducible on duplicate testing of DNA samples extracted from separate paraffin blocks. The real-time PCR product was of the correct size, and the melting curve demonstrated melting temperatures within 1°C from the placenta, the positive control, and a positive sample from an unrelated patient , confirming that the correct product was amplified. At time of the illness in the infant, the mother was negative for Babesia spp. according to PCR and smear but positive for total antibodies (>256). The infant was treated with a 9-day course of azithromycin plus atovaquone. A blood transfusion was administered when her hemoglobin concentration fell to 5.2 g/dL. The infant became afebrile by 72 hours and was discharged after a 5-day hospitalization. Repeat blood smears revealed a parasite load of 0.3% at discharge. On final evaluation at 22 months of age, physical examination revealed no abnormalities; hemoglobin level was 11.7 g/dL, Babesia PCR was negative, and total Babesia antibody level was positive at 128.

Conclusions

Congenital babesiosis has been rarely reported (Table) (–). This case provided convincing evidence for congenital babesiosis because of prepartum infection involving the placenta in the mother. On the basis of experience with congenital malaria, we assume that Babesia spp. parasites cross the placenta during pregnancy or at the time of delivery (,). In congenital malaria, increasing evidence suggests that the malaria parasites are most often acquired antenatally by transplacental transmission of infected erythrocytes ().
Table

Comparison of selected clinical and laboratory data from reported cases of congenital babesiosis in 5 infants*

Clinical dataReference
(7) (8) (9) (10)This study
Year of diagnosis/ locationNot given/Long Island, New YorkNot given/Long Island, New YorkNot given/New JerseyNot given/Long Island, New York2002/Westchester County, New York
Infant age at time of symptom onset, d3032192741
Clinical findingsFever, irritability, pallor, hepatosplenomegalyFever, lethargy, poor feeding, pallor, scleral icterus, hepatomegalyFever, poor feeding, gagging, irritability, pallor, scleral icterus, hepato-splenomegalyFever, pallorFever, decreased oral intake, irritability, scleral icterus, pallor, hepatosplenomegaly
Initial babesia parasitemia level, %54.41524
Hospitalization, d658NA5
Maternal tick bite1 wk before delivery7 wk before delivery4 wk before deliveryNone knownNone known
Babesia spp. serologic and PCR results for infant30 d after birth: IgM+/IgG+ (128/128) by IFA; 32 d after birth: IgM+/IgG+ (256/512) by IFA; PCR NDAt illness onset: IgG IFA 160; IgM/IgG immunoblot +; PCR NDAt illness onset: IgM+/IgG+ (40/256) by IFA; PCR NDNANewborn screening (heel stick): IgM– (<16); total antibody + (>128) by IFA; PCR–; 6 wks after birth: IgM– (<16); total antibody + (>256) by IFA; PCR+
Babesia spp. evaluation results for mother30 d after birth: IgM+/IgG+ (2,048/1,024); 32 d after birth: IgM+/ IgG+ (4,096/1,024); peripheral smear – at time of delivery and at 30 and 32 d after birth7 wk before birth: IgG IFA <40; IgM/IgG immunoblot –; 2 mo after birth: IgG IFA 640; IgM/IgG immunoblot +; peripheral smear – at delivery and at infant illness onsetAt infant illness onset: IgM+/IgG+ (80/>1,024) by IFA; peripheral smear negative at time of infant illness onsetAt infant illness onset: PCR+Birth: placenta PCR+; 6 wk after birth: IgM ND; total antibody + (>256) by IFA; PCR–; peripheral smear –
HGB, g/dL9.310.88.8NA; HCT 24.3%7.1
Platelets, x 103/μL388734101100
Leukocytes/PMN leukocytes, cells/μL6,500/1,170NA9,000/1,890NA19,700/788
LDH, U/L894NA2535NANA
Bilirubin indirect, mg/dL3.69.75.9NA1.6
AST, U/L90NA53NA66
ALT, U/L90NA18NA50
TreatmentCLI and quinine for 10 dCLI and quinine with AZT added on day 3; on day 5 changed to AZT plus quinine for additional 7 dAZT and ATO for 10 dAZT and ATO, duration not givenAZT and ATO for 9 d
Follow-upWell at 6 mo posttreatmentImproved at 2 wkLost to follow-upNA22 mo
Blood transfusion for anemiaYes, for HCT of 18%Yes, for HGB of 7.3 g/dLYes, for HGB of 7.0 g/dLYes, for HCT of 17.3%Yes, for HGB of 5.2 g/dL with HCT of 15.8%

*No mothers became ill. PMN, polymorphonuclear; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase level; HCT, hematocrit; HGB, hemoglobin; IFA, indirect immunofluorescence assay. CLI, clindamycin; AZT, azithromycin; ATO, atovaquone. NA, not available; ND, not done. +, positive; –, negative.

*No mothers became ill. PMN, polymorphonuclear; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase level; HCT, hematocrit; HGB, hemoglobin; IFA, indirect immunofluorescence assay. CLI, clindamycin; AZT, azithromycin; ATO, atovaquone. NA, not available; ND, not done. +, positive; –, negative. Reported cases of congenital babesiosis share many similarities, including asymptomatic maternal infection and development of fever, hemolytic anemia, and thrombocytopenia in the infant detected between 19 and 41 days after birth. All of the infants responded to antimicrobial drug therapy; 3 were treated with azithromycin plus atovaquone (,), the preferred treatment regimen for mild babesiosis (). All infants required a blood transfusion because of severe anemia. The clinical signs and symptoms for these cases of congenital babesiosis are similar to those of congenital malaria in non–disease endemic areas (,). We found Babesia spp. antibodies on day 3 of life by analyzing the patient’s heel-stick blood sample, which likely represented maternal transfer of IgG. Passive transfer of maternal antibodies is regarded as a protective factor against congenital malaria, and some newborns with malaria who are parasitemic at birth spontaneously clear the infection without ever becoming ill (,). The temporary presence of maternal IgG in infants has been suggested as an explanation for the typical 3–6 week incubation period of congenital malaria in non–disease endemic areas (). The real-time PCR used to find B. microti DNA in placenta tissue is ≈20× more sensitive than microscopic examination of Giemsa-stained blood smears (). Assuming a blood sample with a parasitemia equivalent to that detected in the placental tissue, a blood smear would contain <10 infected cells per slide. Given the low level of Babesia DNA in the placenta tissue, it is not surprising that histologic examination did not reveal piroplasms. Nonetheless, limited evidence of placental abnormalities suggests a pathologic process. In summary, babesiosis is an emerging infectious disease () that can rarely cause congenital infection. This diagnosis should be considered in the differential diagnosis of fever and hemolytic anemia in infants from disease-endemic areas.

Technical Appendix

Detailed methods of testing for Babesia spp. in 6-week-old infant with suspected congenital babesiosis.
  15 in total

1.  Vertically transmitted babesiosis.

Authors:  D L New; J B Quinn; M Z Qureshi; S J Sigler
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Transplacental/perinatal babesiosis.

Authors:  D Esernio-Jenssen; P G Scimeca; J L Benach; M J Tenenbaum
Journal:  J Pediatr       Date:  1987-04       Impact factor: 4.406

3.  Umbilical cord-blood infections with Plasmodium falciparum malaria are acquired antenatally in Kenya.

Authors:  Indu Malhotra; Peter Mungai; Eric Muchiri; Jesse J Kwiek; Steven R Meshnick; Christopher L King
Journal:  J Infect Dis       Date:  2006-06-12       Impact factor: 5.226

4.  Cerebral babesiosis in a new-born calf.

Authors:  A J De Vos; G D Imes; J S Cullen
Journal:  Onderstepoort J Vet Res       Date:  1976-06       Impact factor: 1.792

5.  Fatal experimental transplacental Babesia gibsoni infections in dogs.

Authors:  Shinya Fukumoto; Hiroshi Suzuki; Ikuo Igarashi; Xuenan Xuan
Journal:  Int J Parasitol       Date:  2005-08       Impact factor: 3.981

6.  A new real-time PCR assay for improved detection of the parasite Babesia microti.

Authors:  Allen E Teal; Andrea Habura; Jill Ennis; Janet S Keithly; Susan Madison-Antenucci
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

7.  Congenital malaria in the United States: a review of cases from 1966 to 2005.

Authors:  Catherine R Lesko; Paul M Arguin; Robert D Newman
Journal:  Arch Pediatr Adolesc Med       Date:  2007-11

Review 8.  Congenital malaria in neonates: two case reports and review of the literature.

Authors:  Gaelle Vottier; Marie Arsac; Caroline Farnoux; Patricia Mariani-Kurkdjian; Olivier Baud; Yannick Aujard
Journal:  Acta Paediatr       Date:  2008-02-27       Impact factor: 2.299

9.  Detection of Babesia microti by polymerase chain reaction.

Authors:  D H Persing; D Mathiesen; W F Marshall; S R Telford; A Spielman; J W Thomford; P A Conrad
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

Review 10.  Congenital malaria, an important differential diagnosis to consider when evaluating febrile infants of immigrant mothers.

Authors:  Stefan Hagmann; Kartika Khanna; Masooma Niazi; Murli Purswani; Edwin B Robins
Journal:  Pediatr Emerg Care       Date:  2007-05       Impact factor: 1.454

View more
  37 in total

Review 1.  Transmission and epidemiology of zoonotic protozoal diseases of companion animals.

Authors:  Kevin J Esch; Christine A Petersen
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

Review 2.  Babesiosis.

Authors:  Edouard G Vannier; Maria A Diuk-Wasser; Choukri Ben Mamoun; Peter J Krause
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 3.  Babesia microti: from Mice to Ticks to an Increasing Number of Highly Susceptible Humans.

Authors:  Lars F Westblade; Matthew S Simon; Blaine A Mathison; Laura A Kirkman
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

4.  Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?

Authors:  Dana G Mordue; Gary P Wormser
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

5.  Development of droplet digital PCR for the detection of Babesia microti and Babesia duncani.

Authors:  Melisa Wilson; Kathleen C Glaser; Debra Adams-Fish; Matthew Boley; Maria Mayda; Robert E Molestina
Journal:  Exp Parasitol       Date:  2014-12-08       Impact factor: 2.011

6.  Risk Factors for Severe Infection, Hospitalization, and Prolonged Antimicrobial Therapy in Patients with Babesiosis.

Authors:  Neeharik Mareedu; Anna M Schotthoefer; Jason Tompkins; Matthew C Hall; Thomas R Fritsche; Holly M Frost
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

7.  Transfusion-transmitted and community-acquired babesiosis in New York, 2004 to 2015.

Authors:  Jeanne V Linden; Melissa A Prusinski; Lauren A Crowder; Laura Tonnetti; Susan L Stramer; Debra A Kessler; Jennifer White; Beth Shaz; Danuta Olkowska
Journal:  Transfusion       Date:  2018-01-31       Impact factor: 3.157

Review 8.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

9.  Splenic findings in patients with acute babesiosis.

Authors:  A Mojtahed; D D B Bates; P F Hahn
Journal:  Abdom Radiol (NY)       Date:  2020-03

Review 10.  Emerging Tick-Borne Diseases.

Authors:  Susan Madison-Antenucci; Laura D Kramer; Linda L Gebhardt; Elizabeth Kauffman
Journal:  Clin Microbiol Rev       Date:  2020-01-02       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.